Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement.
BACKGROUND
Patients with panhypopituitarism have impaired quality of life (QoL) despite GH replacement. They are profoundly androgen deficient, and dehydroepiandrosterone (DHEA) has been shown to have a beneficial effect on well-being and mood in patients with adrenal failure and possibly in hypopituitarism.


OBJECTIVE
Our objective was to determine the effect of DHEA administration on mood in hypopituitary adults on established GH replacement with a constant serum IGF-I.


METHODS
A double-blind, placebo-controlled trial was conducted over an initial 6 months followed by an open phase of 6 months of DHEA.


METHODS
The study was conducted at a tertiary referral endocrinology unit.


METHODS
Thirty female and 21 male hypopituitary patients enrolled. Data from 26 females and 18 males were analyzed after patient withdrawal.


METHODS
DHEA (50 mg) was added to maintenance replacement including GH.


METHODS
The primary outcome objective was the effect on QoL and libido assessed by QoL assessment in GH deficiency in adults, Short Form 36, General Health Questionnaire, EuroQol, and sexual self-efficacy scale.


RESULTS
Patients had impaired QoL at baseline compared with the age-matched British population. Females showed improvement in QoL assessment in GH deficiency in adults score (-2.9 +/- 2.8 DHEA vs.-0.53 +/- 3 placebo; P < 0.05), in Short Form 36 social functioning (14.6 +/- 23.1 DHEA vs.-4.7 +/- 25 placebo; P = 0.047), and general health perception (9.6 +/- 14.2 DHEA vs.-1.2 +/- 11.6 placebo; P = 0.036) after 6 months of DHEA. Men showed improvement in self-esteem (-1.3 +/- 1.7 DHEA vs. 0.5 +/- 1.5 placebo; P = 0.03) and depression (-1.6 +/- 2.2 DHEA vs. 1.2 +/- 2.4 placebo, P = 0.02) domains of the General Health Questionnaire after 6 months of DHEA.


CONCLUSIONS
DHEA replacement leads to modest improvement in psychological well-being in female and minor psychological improvement in male hypopituitary patients on GH replacement.
Brooke
Antonia M
AM
Department of Endocrinology, Harvey Research Institute, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE, United Kingdom.
Kalingag
Leonila A
LA
Miraki-Moud
Farideh
F
Camacho-Hübner
Cecilia
C
Maher
Katharine T
KT
Walker
Dorothy M
DM
Hinson
Joy P
JP
Monson
John P
JP
D003687:Dehydroepiandrosterone / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006305:Health Status Indicators; D020249:Hormone Replacement Therapy; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy* / Q000523:psychology; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D011788:Quality of Life; D011795:Surveys and Questionnaires
D003687:Dehydroepiandrosterone; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone